Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib — boosting late-stage focus
Gilead $GILD and its partners at Galapagos $GLPG picked up some “very impressive” mid-stage data for their star immunology drug filgotinib, which handily beat out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
